DDInter1592 DDInter111
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apremilast
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apremilast
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Apremilast
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Apremilast
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Rifapentine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Apremilast